These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1712671)

  • 1. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
    Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON
    Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
    Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
    Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
    Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
    Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
    Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction.
    Muller AJ; Pendergast AM; Havlik MH; Puil L; Pawson T; Witte ON
    Mol Cell Biol; 1992 Nov; 12(11):5087-93. PubMed ID: 1383690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.
    Muller AJ; Pendergast AM; Parmar K; Havlik MH; Rosenberg N; Witte ON
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3457-61. PubMed ID: 7682703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
    Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
    Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
    Allen PB; Morgan GJ; Wiedemann LM
    Baillieres Clin Haematol; 1992 Oct; 5(4):897-930. PubMed ID: 1308169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
    Tauchi T; Miyazawa K; Feng GS; Broxmeyer HE; Toyama K
    J Biol Chem; 1997 Jan; 272(2):1389-94. PubMed ID: 8995449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
    McWhirter JR; Galasso DL; Wang JY
    Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential complementation of Bcr-Abl point mutants with c-Myc.
    Afar DE; Goga A; McLaughlin J; Witte ON; Sawyers CL
    Science; 1994 Apr; 264(5157):424-6. PubMed ID: 8153630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of Bcr in leukemias with the Philadelphia chromosome.
    Arlinghaus RB
    Crit Rev Oncog; 1998; 9(1):1-18. PubMed ID: 9754444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bcr-abl gene in chronic myelogenous leukaemia.
    Sawyers CL
    Cancer Surv; 1992; 15():37-51. PubMed ID: 1451113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.
    Mayer BJ; Jackson PK; Baltimore D
    Proc Natl Acad Sci U S A; 1991 Jan; 88(2):627-31. PubMed ID: 1703304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
    Arlinghaus RB
    Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.